Zevra Therapeutics (ZVRA) Short-term Investments (2015 - 2026)

Zevra Therapeutics' Short-term Investments history runs 9 years deep, the most recent figure standing at $105.0 million for Q1 2026.

• Quarterly Short-term Investments rose 315.25% year-over-year to $105.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $105.0 million (up 315.25% YoY) and the FY2025 annual result came in at $128.6 million, up 260.13% from the prior year.
• Short-term Investments was $105.0 million for Q1 2026 at Zevra Therapeutics, down from $128.6 million in the prior quarter.
• Across five years, Short-term Investments topped out at $154.9 million in Q2 2025 and bottomed at $479000.0 in Q2 2023.
• A 5-year average of $56.3 million and a median of $30.3 million in 2024 frame the typical range for Short-term Investments.
• Annual changes were most pronounced in 2023 — Short-term Investments surged 5032.64% — and 2024, when it jumped 44.65%.
• Zevra Therapeutics' Short-term Investments stood at $481000.0 in 2022, then jumped by 5032.64% to $24.7 million in 2023, then surged by 44.65% to $35.7 million in 2024, then jumped by 260.13% to $128.6 million in 2025, then decreased by 18.34% to $105.0 million in 2026.
• Business Quant data shows ZVRA's Short-term Investments at $105.0 million in Q1 2026, $128.6 million in Q4 2025, and $145.1 million in Q3 2025.